MA33747B1 - Anticorps monoclonaux diriges contre la progastrine et leurs utilisations - Google Patents

Anticorps monoclonaux diriges contre la progastrine et leurs utilisations

Info

Publication number
MA33747B1
MA33747B1 MA34864A MA34864A MA33747B1 MA 33747 B1 MA33747 B1 MA 33747B1 MA 34864 A MA34864 A MA 34864A MA 34864 A MA34864 A MA 34864A MA 33747 B1 MA33747 B1 MA 33747B1
Authority
MA
Morocco
Prior art keywords
monoclonal antibodies
antibodies against
methods
progastrin
gastrin
Prior art date
Application number
MA34864A
Other languages
Arabic (ar)
English (en)
Inventor
Julie Pannequin
Laure Boudier
Dominique Joubert
Frédéric Hollande
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Biorealites
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33747(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Biorealites filed Critical Inst Nat Sante Rech Med
Publication of MA33747B1 publication Critical patent/MA33747B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux contre la progastrine, des fragments de ceux-ci, des compositions comprenant les anticorps monoclonaux contre la progastrine, et des procédés de fabrication et d'utilisation d'anticorps monoclonaux contre la progastrine ainsi que des compositions les contenant. La présente invention concerne des procédés de traitement du cancer colorectal avec des anticorps monoclonaux contre la progastrine et des compositions comprenant des anticorps monoclonaux contre la progastrine ou des fragments de ceux-ci. La présente invention concerne en outre des procédés comprenant la détection de la progastrine, y compris des procédés de diagnostic du cancer colorectal et des procédés de surveillance de l'efficacité d'une thérapie anticancéreuse chez des sujets souffrant du cancer colorectal.
MA34864A 2009-10-16 2012-05-11 Anticorps monoclonaux diriges contre la progastrine et leurs utilisations MA33747B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
PCT/EP2010/006329 WO2011045080A2 (fr) 2009-10-16 2010-10-15 Anticorps monoclonaux contre la progastrine et leurs utilisations

Publications (1)

Publication Number Publication Date
MA33747B1 true MA33747B1 (fr) 2012-11-01

Family

ID=43086711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34864A MA33747B1 (fr) 2009-10-16 2012-05-11 Anticorps monoclonaux diriges contre la progastrine et leurs utilisations

Country Status (42)

Country Link
US (7) US9611320B2 (fr)
EP (2) EP2488551B1 (fr)
JP (3) JP5985987B2 (fr)
KR (2) KR20120091221A (fr)
CN (2) CN102791735B (fr)
AP (1) AP2012006262A0 (fr)
AR (1) AR078659A1 (fr)
AU (1) AU2010306119A1 (fr)
BR (1) BR112012008818B1 (fr)
CA (1) CA2777691C (fr)
CL (1) CL2012000914A1 (fr)
CR (1) CR20120184A (fr)
CU (1) CU24196B1 (fr)
CY (1) CY1120913T1 (fr)
DK (1) DK2488551T3 (fr)
EA (2) EA201791876A1 (fr)
EC (1) ECSP12011796A (fr)
ES (2) ES2973217T3 (fr)
GE (1) GEP201706604B (fr)
GT (1) GT201200114A (fr)
HN (1) HN2012000708A (fr)
HR (1) HRP20181645T1 (fr)
IL (2) IL219019B (fr)
IN (1) IN2012DN03348A (fr)
LT (1) LT2488551T (fr)
MA (1) MA33747B1 (fr)
MX (1) MX351635B (fr)
NI (1) NI201200054A (fr)
NZ (2) NZ599971A (fr)
PE (1) PE20121649A1 (fr)
PH (1) PH12012500711B1 (fr)
PL (2) PL3421493T3 (fr)
PT (1) PT2488551T (fr)
RS (1) RS57966B1 (fr)
SG (1) SG10201704933PA (fr)
SI (1) SI2488551T1 (fr)
SM (1) SMT201800628T1 (fr)
TN (1) TN2012000159A1 (fr)
TW (1) TWI537002B (fr)
UA (1) UA106771C2 (fr)
WO (1) WO2011045080A2 (fr)
ZA (1) ZA201202642B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
EP2488551B1 (fr) * 2009-10-16 2018-07-25 Progastrine et Cancers S.à r.l. Anticorps monoclonaux contre la progastrine et leurs utilisations
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
JP5829672B2 (ja) * 2010-03-24 2015-12-09 レ ラボラトワール セルヴィエ 結腸直腸及び胃腸癌の予防
US10533050B2 (en) * 2010-07-26 2020-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for liver cancer therapy
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
WO2012164035A1 (fr) 2011-06-01 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour prédire le risque de développer une néoplasie du côlon
WO2015003114A1 (fr) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Anticorps monoclonal neutralisant la protéine mic soluble pour le traitement du cancer
RU2699717C2 (ru) * 2014-04-18 2019-09-09 Дзе Ресёч Фаундэйшен Фор Дзе Штат Юниверсити Ов Нью-Йорк Гуманизированные антитела к антигену Томсена-Фриденрайха
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
WO2016066671A1 (fr) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour traiter des cancers résistants à l'aide d'inhibiteurs de la progastrine
WO2017048629A1 (fr) * 2015-09-15 2017-03-23 The Scripps Research Institute Anticorps pour la production de macrophages anti-inflammatoires et utilisations associées
MA43550A (fr) * 2015-12-31 2018-11-07 Syncerus S A R L Compositions et procédés d'évaluation du risque d'apparition d'un cancer
KR102477179B1 (ko) 2015-12-31 2022-12-13 프로가스트린 에 캔서스 에스.에이 알.엘. 위암의 검출 및 치료를 위한 조성물 및 방법
ES3015244T3 (en) * 2015-12-31 2025-04-30 Ecs Progastrin Sa Compositions and methods for detecting and treating ovarian cancer
SG11201908996YA (en) * 2017-03-30 2019-10-30 Ecs Progastrin Sa Compositions and methods for detecting lung cancer
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
WO2019110662A1 (fr) * 2017-12-05 2019-06-13 Progastrine Et Cancers S.À R.L. Polythérapie entre un anticorps anti-progastrine et une immunothérapie pour traiter le cancer
JP7338128B2 (ja) 2017-12-08 2023-09-05 イー、シー、エス、ビオトラッカー、エス、エー、アール、エル 癌診断における放射性標識プロガストリン
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (fr) * 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrine en tant que biomarqueur pour l'immunothérapie
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
WO2021066751A1 (fr) * 2019-10-02 2021-04-08 Aslan Pharmaceuticals Pte. Ltd. Domaines de liaison à l'antigène spécifiques et molécules d'anticorps
CN112062846A (zh) * 2020-04-27 2020-12-11 杭州博茵生物技术有限公司 一种g-17单克隆抗体及其应用
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN115724949A (zh) * 2022-12-12 2023-03-03 郑州伊美诺生物技术有限公司 一种鼠源lgG单克隆抗体及其制备方法、应用
CN116143920A (zh) * 2022-12-30 2023-05-23 南京岚煜生物科技有限公司 胃泌素17的单克隆抗体及其细胞株的制备方法和应用
US20250059271A1 (en) * 2023-08-16 2025-02-20 Barrelman Biosciences Llc Monoclonal antibodies against veterinary progastrin-like molecules and their uses
CN118126177A (zh) * 2023-11-22 2024-06-04 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DK1794586T3 (da) * 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
US20100209426A1 (en) * 2006-05-22 2010-08-19 Inserm (Institut National De La Sante Et De La Rec Herche Medicale) Inhibitors of progastrin-induced repression of icat for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/tcf-mediated transcriptional pathway is constitutively active
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
EP2337795A2 (fr) * 2008-10-01 2011-06-29 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
EP2488551B1 (fr) * 2009-10-16 2018-07-25 Progastrine et Cancers S.à r.l. Anticorps monoclonaux contre la progastrine et leurs utilisations
JP5829672B2 (ja) * 2010-03-24 2015-12-09 レ ラボラトワール セルヴィエ 結腸直腸及び胃腸癌の予防
US10533050B2 (en) * 2010-07-26 2020-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for liver cancer therapy

Also Published As

Publication number Publication date
JP2013507138A (ja) 2013-03-04
US20220195035A1 (en) 2022-06-23
EA029271B1 (ru) 2018-03-30
MX351635B (es) 2017-10-23
KR101640520B1 (ko) 2016-07-19
PH12012500711A1 (en) 2012-11-12
US11299542B2 (en) 2022-04-12
BR112012008818B1 (pt) 2021-10-19
IL254004B2 (en) 2023-06-01
EA201791876A1 (ru) 2018-01-31
RS57966B1 (sr) 2019-01-31
CU20120060A7 (es) 2013-04-19
IL254004A0 (en) 2017-10-31
LT2488551T (lt) 2018-10-25
US10377821B2 (en) 2019-08-13
KR20150082672A (ko) 2015-07-15
HK1178183A1 (zh) 2013-09-06
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
AU2010306119A1 (en) 2012-05-03
PL2488551T3 (pl) 2019-01-31
CN104628857A (zh) 2015-05-20
MX2012004400A (es) 2012-06-27
EA201200597A1 (ru) 2012-12-28
TN2012000159A1 (en) 2013-12-12
DK2488551T3 (en) 2018-10-08
IL219019B (en) 2019-05-30
GEP201706604B (en) 2017-01-25
SG10201704933PA (en) 2017-07-28
EP2488551B1 (fr) 2018-07-25
PT2488551T (pt) 2018-10-31
TWI537002B (zh) 2016-06-11
US20110117086A1 (en) 2011-05-19
CU24196B1 (es) 2016-09-30
US10385124B2 (en) 2019-08-20
US20170306011A1 (en) 2017-10-26
CA2777691A1 (fr) 2011-04-21
PL3421493T3 (pl) 2024-04-29
CR20120184A (es) 2012-08-20
HRP20181645T1 (hr) 2018-12-14
NZ701709A (en) 2016-06-24
TW201119675A (en) 2011-06-16
EP3421493C0 (fr) 2024-01-17
HN2012000708A (es) 2015-06-22
UA106771C2 (uk) 2014-10-10
GT201200114A (es) 2014-08-11
AP2012006262A0 (en) 2012-06-30
CY1120913T1 (el) 2019-12-11
JP2017212992A (ja) 2017-12-07
NI201200054A (es) 2012-08-20
JP5985987B2 (ja) 2016-09-06
JP2015145380A (ja) 2015-08-13
SI2488551T1 (sl) 2019-01-31
CL2012000914A1 (es) 2012-09-14
NZ599971A (en) 2014-12-24
ECSP12011796A (es) 2012-06-29
US20170174761A1 (en) 2017-06-22
US20170306012A1 (en) 2017-10-26
IL219019A0 (en) 2012-06-28
IN2012DN03348A (fr) 2015-10-23
WO2011045080A2 (fr) 2011-04-21
ES2690943T3 (es) 2018-11-23
EP3421493A1 (fr) 2019-01-02
PH12012500711B1 (en) 2019-04-24
SMT201800628T1 (it) 2019-01-11
KR20120091221A (ko) 2012-08-17
JP6272793B2 (ja) 2018-01-31
US20180022802A1 (en) 2018-01-25
EP2488551A2 (fr) 2012-08-22
EP3421493B1 (fr) 2024-01-17
ZA201202642B (en) 2013-06-26
US9611320B2 (en) 2017-04-04
WO2011045080A3 (fr) 2011-07-07
PE20121649A1 (es) 2012-12-08
US10385126B2 (en) 2019-08-20
CA2777691C (fr) 2018-02-27
CN102791735A (zh) 2012-11-21
BR112012008818A2 (en) 2018-05-22
US10385125B2 (en) 2019-08-20
US20200002413A1 (en) 2020-01-02
ES2973217T3 (es) 2024-06-19

Similar Documents

Publication Publication Date Title
MA33747B1 (fr) Anticorps monoclonaux diriges contre la progastrine et leurs utilisations
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
EP2209495A4 (fr) Taz/wwtr1 pour diagnostic et traitement de cancer
EP2019619A4 (fr) Procédés, systèmes appareil de suivi d'évolution, diagnostic et traitement de condition inflammatoire, et utilisations
WO2011015944A3 (fr) Utilisation d'adn libre en tant que prédicteur précoce de la gravité d'une pancréatite aiguë
EP4357783A3 (fr) Système et procédés hautement sensibles pour l'analyse de troponine
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
WO2010027903A8 (fr) Diagnostic du cancer du poumon
EP2539470A4 (fr) Procédés pour le diagnostic, le pronostic et le traitement de maladies auto-immunes
WO2009077864A3 (fr) Compositions et procédés de détection d'anticorps tiab
EP1934377A4 (fr) Procédés et compositions permettant d'identifier des biomarqueurs utiles au diagnostic et/ou au traitement d'états biologiques
PT2129391E (pt) Método de diagnóstico
EP2569635A4 (fr) Procédés de diagnostic et traitement de l'encéphalite ou de l'épilepsie
MA30393B1 (fr) Procede de traitement, de diagnostic ou de detection du cancer
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2007084397A3 (fr) Méthode de traitement de slpi par chymase
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
BR112015021507A2 (pt) métodos e composições para o diagnóstico de pré-eclampsia
MX2023001937A (es) Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento.
WO2014169011A3 (fr) Procédés de traitement de maladies immunes
NZ601643A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MA30565B1 (fr) Procede de diagnostic et traitement anticancereux
IN2014MN01760A (fr)